Clinical Trials Directory

Trials / Unknown

UnknownNCT03309709

Endometrial Polyps Regression With Progesterone Therapy

Efficacy of Subcutaneous Progesterone in Premenopausal Woman With Endometrial Polyp: a Multicentric Randomized Control Trial

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
University Magna Graecia · Academic / Other
Sex
Female
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

This prospective randomized study will compare the regression rates of women managed with watch-and-wait approach and of those treated with 3 cycles of luteal 25mg subcutaneous progesterone from 18 to 25 days of menstrual cycle

Detailed description

In premenopause, 25% of endometrial polyps regresses spontaneously in 1 year. According to guidelines, given that most premenopausal polyps are not malignant, there is an option for expectant approach with no surgical intervention. Studies on the efficacy of medical treatments for endometrial polyps are also recommended by gynaecologic societies, with the aim of finding cost-saving not invasive strategies to manage this common pathology. Up to now, nobody has investigated the effect of progestin administration on polyps, but molecular and clinical data suggest that the antiestrogenic effect of this hormone can be exploited to increase and speed-up their regression rate. Our preliminary results on the effect of three months of progesterone demonstrated a regression rate of 47,5% in women treated vs 12,5% in those don't receiving treatment. Accordingly, in this prospective randomized study we aim to compare the regression rates of women managed with watch-and-wait approach and of those treated with 3 cycles of luteal 25mg subcutaneous progesterone from 18 to 25 days of menstrual cycle

Conditions

Interventions

TypeNameDescription
DRUGsubcutaneous progesterone25mg daily for 7 days

Timeline

Start date
2017-10-08
Primary completion
2019-10-30
Completion
2019-12-30
First posted
2017-10-13
Last updated
2019-01-15

Locations

2 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT03309709. Inclusion in this directory is not an endorsement.